A case of malignant schwannoma with overexpression of multidrug resistance gene (MDR1) after chemotherapy

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2273-2277

  Suto, Ryuji ^a   Abe, Yoshiyuki ^a   Lee, Yoon Hwan ^a   Ueyama, Yoshito ^a,b   Yamazaki, Hitoshi ^a   Kijima, Hiroshi ^a   Hiraoka, Nobuyoshi ^a   Fukuda, Hiroaki ^a   Tamaoki, Norikazu ^a   Nakamura, Masato ^a,b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA ACADEMY OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Malignant schwannoma; Multidrug resistance; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; GLYCOPROTEIN P; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CASE REPORT; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; LYMPH NODE METASTASIS; MALIGNANT NEURILEMOMA; MULTIDRUG RESISTANCE; NORTHERN BLOTTING; PRIORITY JOURNAL;

ACTINS; ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; BLOTTING, NORTHERN; BONE NEOPLASMS; CYCLOPHOSPHAMIDE; DACARBAZINE; DESMIN; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; MYOGLOBIN; MYOSINS; NEOPLASM METASTASIS; NEURILEMMOMA; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; S100 PROTEINS; VINCRISTINE;

EID: 0030810711     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Houghton JA, Williams LG, Houghton PJ: Stability of vincristine complexes in cytosols derived from xenografts of human rhabdomyosarcoma andnormal tissues ofthe mouse. Cancer Res 45: 3761-3767, 1985.
2. Zwelling LA, Slovak ML, Doroshow JH, Hinds M, Chan D, Parker E, Mayes J, Sie KL, Meltzer PS, Trent JM: HT1080/DR: A p-glyco- protein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug- sensitive topoisomerase II. J Natl Cancer Inst 82: 1553-1561, 1990.
3. Roninson IB: Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Plenum, New York, 91-104, 1991.
4. Gros P, Neriah YB, Croop JM, Housman DE: Isolation and expression of a complementary DNA that confers multidrug resistance. Nature 323: 728-731, 1986.
5. Imanishi T, Abe Y, Suto R, Higaki S, Ueyama Y, Nakamura M, Tamaoki N, Hukuda H, Imai N: Expression ofthe human multidrug resistance gene (MDR1) and prognostic correlation in human osteogenic sarcoma. Tokai J Exp Clin Med 19: 39-46, 1994.
6. Abe Y, Nakamura M., Ota E, Ozeki Y, Tamai S, Inoue H, Ueyama Y, Ogata T and Tamaoki N: Expression of the multidrug resistance gene (MDR1) in non-small cell lung cancer. Jpn J Cancer Res 85: 536-541, 1994.
7. Toth K, Vaughan MN, Slocum HK, Arredondo MA, Takata H, BakerA RM, Rustum YM: New immunohistochemical "Sandwich" staining method for MDR1 P-glycoprotein detection with JSB-1 monoclonal antibody in formarin-fixed, paraffin-embedded human tissues. Am J Pathol 144: 227-236, 1994.
8. Gerlach JH, Bell DR, Karkousis C, Slocum HK, Kartner N, Rustum YM, Ling V, Baker RM: P-glycoprotein in human sarcoma: Evidence for multidrug resistance. J Clin Oncol 5: 1452-1460, 1987.
9. Chen C, Clark D, Ueda K, Pastan I, Gottesman MM, Roninson IB: Genomic organization ofthe human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J Biol Chem 265: 506-514, 1990.
10. Ueda K, Clark DP, Chen C, Roninson IB, Gottesman MM, Pastan I: The human multidrug resistance (mdr1) gene. J Biol Chem 262: 505-508, 1987.
11. Chan HSL, Thoner PS, Haddad G, Ling V: Immunohistochemical detection of p-glycoprotein: Prognostic correlation in soft tissue sarcoma of child. J Clin Oncol 8: 689-704, 1990.
12. Abe Y, Yamazaki H, Oshika Y, Suto R, Tsugu A, Ota E, Satoh H, Ohnishi Y, Yanagawa T, Ueyama Y, Tamaoki N, Nakamura M: Advantage of in vivo chemosensitivity assay to detect vincristine- resistance in a human epidermoid carcinoma xenograft. Anticancer Res 16: 729-734, 1996.
13. Abe Y, Ohnishi Y, Yoshimura M, Ota E, Ozeki Y, Oshika Y, Tokunaga T, Yamazaki H, Ueyama Y, Ogata T, Tamaoki N, Nakamura M: P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo. Br J Cancer 74: 1929-1934, 1996.
14. Brock I, Hipfner DR, Nielsen BS, Jensen PB, DEELEY RG, Cole, SPC, Sehested M: Sequential coexpression of the multidrug resistance genes MRP and MDR1 and their products in VP-16 (etoposide)- selected H69 small cell lung cancer cells. Cancer Res 55: 459-462, 1995.
15. Chaudrey PM, Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639, 1993.
16. Chen G, Jaffrezou J, Fleming WH, Duran GE, Sikic BI: Prevalence of multidrug resistance related to activation ofthe MDR1 gene in human sarcoma mutants derived by single-step doxorubicine selection. Cancer Res 54: 4980-4987, 1994.
17. Mizoguchi T, Yamada K, Furukawa T, Hidaka K, Hisatsugu T, Shimazu H, Tsuruo T, Sumizawa T, Akiyama S: Expression of the MDR1 gene in human gastric and colorectal carcinoma. J Natl Cancer Inst 82: 1679-1683, 1990.
18. Christensen JG, Leblanc GA: Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carboinol. Cancer Res 56: 574-581, 1996.
19. Ford JM, Hait WN: Pharmacology of drugs that alter multidrug resistance in cance. Pharmacol Rev 42: 155-199, 1990.
20. Lum, BL, Fisher GA, Brophy NA,Yahanda AM, Adler KM, Kaubisch S, Halsey J, Sikic BI: Clinical trials of modulation of multidrug resistance. Cancer 72: 3502-3514, 1993.